Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

Bone Marrow Transplantation

Volumn 43, Issue 5, 2009, Pages 383-397

  Buhmann, R ^a,b   Simoes, B ^a,b   Stanglmaier, M ^c   Yang, T ^b   Faltin, M ^c   Bund, D ^b   Lindhofer, H ^d   Kolb, H J ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TRION Research GmbH   (Germany)

^d TRION Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY BI20; CATUMAXOMAB; CD20 ANTIGEN; CD3 ANTIGEN; CISPLATIN; CLEMASTINE; CYTARABINE; CYTOKINE; DEXAMETHASONE; FBTA 05; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PARACETAMOL; PROTEIN P53; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; BONE PAIN; BURKITT LYMPHOMA; CANCER GRADING; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HYPOTENSION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOMA CELL; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA;

ADOPTIVE TRANSFER; ADULT; ANTIBODIES, BISPECIFIC; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 62549086034     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.323     Document Type: Article

References (32)

1. Grigg A, Ritchie D. Graft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579-590.
2. Butcher BW, Collins Jr RH. The graft-versus-lymphoma effect: Clinical review and future opportunities. Bone Marrow Transplant 2005; 36: 1-17.
3. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
4. van Besien KW, de Lima M, Giralt SA, Moore Jr DF, Khouri IF, Rondon G et al. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977-982.
5. Bierman PJ, Sweetenham JW, Loberiza Jr FR, Taghipour G, Lazarus HM, Rizzo JD et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744-3753.
6. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.
7. Kawano I, Tsukada J, Toda Y, Ogawa R, Higashi T, Iwashige A et al. [Remission induction of refractory diffuse large B-cell lymphoma with allogeneic peripheral blood stem cell transplantation followed by interferon-alpha and donor lymphocyte infusion]. Rinsho Ketsueki 2004; 45: 155-160.
8. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107: 1325-1331.
9. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600-2602.
10. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: Ways to improve rituximab efficacy. Blood 2004; 104 2635-2642.
11. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11: 558-562.
12. Kufer P, Lutterbuse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22: 238-244.
13. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98: 2526-2534.
14. Stanglmaier S, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H. Bi20 (FBTA05) a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of lymphoma B cells even with very low CD20 expression levels. Int J Cancer 2008; 123: 1181-1189.
15. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
16. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
17. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-3613.
18. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005, 329-334.
19. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629-3636.
20. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67: 1270-1281.
21. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16: 1675-1682.
22. Brandl M, Grosse-Hovest L, Holler E, Kolb HJ, Jung G. Bispecific antibody fragments with CD20×CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma. Exp Hematol 1999; 27: 1264-1270.
23. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83: 261-266.
24. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005; 117: 435-443.
25. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S. Use of trifunctional bispecific antibodies to prevent graft-versus-host disease induced by allogeneic lymphocytes. Blood 2006; 107: 1564-1569.
26. Ferrara JL, Cooke KR, Pan L, Krenger W. The immuno-pathophysiology of acute graft-versus-host-disease. Stem Cells 1996; 14: 473-489.
27. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000; 105: 1289-1298.
28. Ruf P, Jager M, Ellwart J, Wosch S, Kusterer E, Lindhofer H. Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer 2004; 108: 725-732.
29. Sebastian M, Passlick B, Friccius-Quecke H, Jager M, Lindhofer H, Kanniess F et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): A phase I study. Cancer Immunol Immunother 2007; 56 1637-1644.
30. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 2007; 13: 3899-3905.
31. Kiewe P, Hasmuller S, Kahlert S, Heinrigs M, Rack B, Marme A et al Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006; 12: 3085-3091.
32. Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S et al Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispeci.c antibodies: A pilot study. Anticancer Res 2005; 25: 3047-3054.